@article {Tade282, author = {Funmilayo I. Tade and Rebecca A. Sajdak and Mehdat Gabriel and Robert H. Wagner and Bital Savir-Baruch}, title = {Best Practices for 18F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists}, volume = {47}, number = {4}, pages = {282--287}, year = {2019}, doi = {10.2967/jnmt.119.227116}, publisher = {Society of Nuclear Medicine}, abstract = {18F-fluciclovine is a Food and Drug Administration{\textendash}approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol.}, issn = {0091-4916}, URL = {https://tech.snmjournals.org/content/47/4/282}, eprint = {https://tech.snmjournals.org/content/47/4/282.full.pdf}, journal = {Journal of Nuclear Medicine Technology} }